Previous studies in a general population with T2D have demonstrated cost savings with use of sodium glucose transporter-2 inhibitor (SGLT2i) as compared to either DDP4i or GLP1-RA22–25, however, there have been no prior studies to our knowledge examining direct cross-comparison of healthcare utilization between use of DDP4i and GLP1-RA in CKD in the United States. The gene discussed is GCG; the disease is chronic kidney disease.